CrossrefInfokarte
444 | A PHASE 1 STUDY OF SGR‐1505, AN ORAL, POTENT MALT1 INHIBITOR FOR R/R B‐CELL MALIGNANCIES, INCLUDING CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
Hematological Oncology · 2025-06 · 43 (S3)
DOI: 10.1002/hon.70094_444 ↗Abstract
Kein Abstract verfügbar.
EUVIMED